A Parkinson's biotech debut, fundraising campaign and licensing deal

Positive

AI Analysis

Summary

The Michael J. Fox Foundation is backing Ariadne Bio, a newly launched biotech developing a non-hallucinogenic psychedelic for Parkinson's disease. The article also references company updates from AstraZeneca, Novo, Longeveron, Connexus Therapeutics, Avacta, Altis Labs, and Matisse Pharmaceuticals.

Importance:4/10

Sentiment:

0.30

Parkinson's diseasePsychedelic therapeuticsBiotech IPOLicensing dealFundraising

Related Companies

$AZN $LGVN $AVCT.L

Read the original article

Published by Endpoints News on September 17, 2026 3:28 PM

Read Original